Table 1.
Demographic and Clinical Characteristics of Persons with HF
| Variable | Total N = 117 |
Usual Care n =38 |
PFE n =42 |
FPI n=37 |
p-values ANOVA or χ2 tests |
|---|---|---|---|---|---|
| Age Range years | 28 – 78 | 31 – 74 | 28 – 78 | 38 – 78 | p=.793 |
| M±SD | 55.9 ± 10.5 | 55.8 ± 10.3 | 56.7 ± 11.1 | 55.1 ± 10.2 | |
| Gender M/W% | 63/37 | 68/32 | 55/45 | 68/32 | p=.361 |
| Education | |||||
| % ≥ College | 47.9 | 55.3 | 52.4 | 35.1 | p=.167 |
| Ethnicity | |||||
| % Caucasian | 42 | 37 | 43 | 46 | p=.717 |
| % AA | 58 | 63 | 57 | 54 | |
| Family Member | |||||
| % spouse/partner | 52.6 | 56.8 | 40.5 | 62.2 | p=.203 |
| % adult child/sibling^ | 22.4 | 24.3 | 23.8 | 18.9 | |
| % other^ | 25.0 | 18.9 | 35.7 | 18.9 | |
| NYHA Class | |||||
| % Level II | 72.6 | 76.3 | 69.0 | 73.0 | p=.766 |
| % Level III | 27.4 | 23.7 | 31.0 | 27.0 | |
| LVEF M±SD | 26.9 ± 13.7 | 24.4 ± 11.2 | 25.8 ± 12.8 | 30.7 ± 16.5 | p=.178 |
| N=91 | n=30 | n=32 | n=29 | ||
| Charlson | |||||
| Comorbidity Index M±SD | 3.1 ± 2.2 | 2.9 ± 1.8 | 3.0 ± 2.1 | 3.2 ± 2.7 | p=.846 |
| BMI M±SD | 33.7± 8.4 | 33.1± 7.9 | 33.7± 8.5 | 34.4± 9.0 | p=.799 |
| Serum Creatinine (mg/dl) M±SD | 1.30± .41 | 1.37± .53 | 1.26± .36 | 1.29± .32 | p=.496 |
| Diuretics | |||||
| Thiazides (%) | 7.8 | 7.9 | 9.8 | 5.6 | p=.658 |
| Potassium sparing | |||||
| Spironolactone (%) | 40.9 | 34.2 | 43.9 | 44.4 | p=.593 |
| Furosemide | 33.0 | 31.6 | 34.1 | 33.3 | |
| equivalents (%)* | 42.6 | 39.5 | 43.9 | 44.4 | |
| 0 (0 mg/day) | 17.4 | 18.4 | 17.1 | 16.7 | |
| 1 (≤40 mg/day) | 2.6 | 5.3 | 0.0 | 2.8 | |
| 2 (41–80 mg/day)^ | 4.4 | 5.3 | 4.9 | 2.8 | p=.734 |
| 3 (81–160 mg/day)^ | |||||
| 4 (>160 mg/day)^ | |||||
*
Furosemide equivalents: Furosemide 80 mg = torsemide 40; bumetanide 3 mg; ethacrynic acid 50 mg.39
^
These categories were combined for the purpose of comparing the groups via chi-square analysis.